ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
+0.003 (1.28%)
Apr 28 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.26 - 0.28
52 week 0.20 - 0.63
Open 0.26
Vol / Avg. 0.00/190,230.00
Mkt cap 24.45M
P/E     -
Div/yield     -
EPS -0.14
Shares 91.73M
Beta 0.66
Inst. own 10%
Jun 24, 2016
ImmunoCellular Therapeutics Ltd Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 9, 2016
Q1 2016 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 30, 2016
Q4 2015 ImmunoCellular Therapeutics Ltd Earnings Call
Mar 30, 2016
Q4 2015 ImmunoCellular Therapeutics Ltd Earnings Release
Mar 16, 2016
ImmunoCellular Therapeutics Ltd at ROTH Conference
Feb 8, 2016
ImmunoCellular Therapeutics Ltd at Biotechnology Industry Organization (BIO) CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -63.32% -46.29%
Return on average equity -80.37% -56.83%
Employees 6 -
CDP Score - -


23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company's cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Company's lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.

Officers and directors

Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
John S. Yu M.D. Director
Age: 51
Bio & Compensation  - Reuters
Gregg A. Lapointe CPA Independent Director
Age: 56
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Independent Director
Age: 54
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters